The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A 24-week randomized, double-blind, paralell-group, multi-centre, placebo-controlled study to evaluate the efficacy, safety and tolerability of tesaglitazar therapy when administred as monotherapy to drug-naive patients with type II diabetes.
- collapse A Double Blind, Mulit-Centre, Active Controlled (Pioglitazone) Long term Extension Study to Evaluate the Safety, Tolerability & Efficacy of Tesaglitazar in Patients with Type 2 Diabetes Mellitus (Gallex 6)
- collapse A Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar Therapy in Patients with Type 2 Diabetes
- collapse A 24-Week, Randomised, Parallel-Group, Multi-Centre, Active-Controlled (pioglitazone) Study of the Renal Effects of Tesaglitazar in Patients with Type 2 Diabetes Mellitus
- collapse An open-label, multi-centre and long-term extension study to evaluate the safety and tolerability of tesaglitazar therapy in patients with type 2 diabetes.
- collapse A 24-Week Randomised, Double-Blind, Multicentre, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patients with Type 2 Diabetes Poorly Controlled on Insulin Alone (GALLANT 9)
- collapse A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patients with Type 2 Diabetes Poorly Controlled on Sulphonylurea Alone GALLANT 7
- collapse A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patients with Type 2 Diabetes Poorly Controlled on Metformin Alone GALLANT 8
- collapse A 24 week randomised, double-blind, multi-centre, active-controlled (pioglitazone) study to evaluate the efficacy, safety, and tolerability of tesaglitazar therapy when admininstered to patients with type 2 diabetes (GALLANT 6)
- collapse A 52-Wk Randomised, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin) Study to Evaluate the Efficacy, Safety & Tolerability of Tesaglitazar Therapy When Administered to Patients with Type 2 Diabetes
